Zobrazeno 1 - 10
of 53
pro vyhledávání: '"E Bonnem"'
Autor:
B Poiesz, E Bonnem, L C Bartos, M L Maliszewski, W D Lawrence, Gene D. Morse, J Santora, Ross G. Hewitt
Publikováno v:
Antimicrobial Agents and Chemotherapy. 37:512-522
Granulocytopenia is a complication of human immunodeficiency virus disease, as well as a toxic manifestation of zidovudine therapy. To evaluate pharmacokinetic and pharmacodynamic relationships, 11 AIDS-AIDS-related complex patients who had developed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0f4d292fc563a771b7423ac3ad358c4
https://doi.org/10.1128/aac.37.3.512
https://doi.org/10.1128/aac.37.3.512
Autor:
E. Bonnem, H. Ozer, L. Tensen, Harvey M. Golomb, J. Thompson, James W. Vardiman, A. Fefer, J. S. Burke, C. Portlock, R. Silber, Mark J. Ratain, J. Rappeport, R. Spiegel, David W. Golde
Publikováno v:
Leukemia & Lymphoma. 4:99-102
One hundred ninety-five patients were entered into a multi-institutional study of interferon alfa 2b from 1983-1986; follow-up was completed through June 1989. A complete remission was documented in 7 patients, a partial remission in 152 patients, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b10b0d4ff1ac0efd70cd5187a5e83d4
https://doi.org/10.3109/10428199109068051
https://doi.org/10.3109/10428199109068051
Autor:
G J, Lieschke, D, Maher, M, O'Connor, M, Green, W, Sheridan, M, Rallings, E, Bonnem, A W, Burgess, K, McGrath, R M, Fox
Publikováno v:
Cancer research. 50(3)
A Phase I study of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) was undertaken in 21 patients with advanced malignancy or neutropenia. rhGM-CSF was administered once daily by i.v. bolus injecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c5b0d5c037e60c8032d3ff62a8524b74
https://pubmed.ncbi.nlm.nih.gov/2404573
https://pubmed.ncbi.nlm.nih.gov/2404573
Autor:
E. Bonnem, P. von Wussow
Publikováno v:
Interferone ISBN: 9783642933844
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2ba5f78e92cf7d50d2d3590af17007e
https://doi.org/10.1007/978-3-642-93383-7_23
https://doi.org/10.1007/978-3-642-93383-7_23
Publikováno v:
Nuclear Physics. 63:513-519
The calculated binding energies and r.m.s. radii are given for the ground states of the three and four-nucleon systems for nine assumed central potentials. Two of the potentials have hard cores and six have velocity-dependent terms. The results are g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb8d4728e472bb3bd4964f47a5cbb6cb
https://doi.org/10.1016/0029-5582(65)90481-5
https://doi.org/10.1016/0029-5582(65)90481-5
Autor:
H M, Golomb, A, Fefer, D W, Golde, H, Ozer, C, Portlock, R, Silber, J, Rappeport, M J, Ratain, J, Thompson, E, Bonnem
Publikováno v:
Seminars in oncology. 15(5 Suppl 5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6000efdc7e6a2833b3432b7b04f6c683
https://pubmed.ncbi.nlm.nih.gov/3057646
https://pubmed.ncbi.nlm.nih.gov/3057646
Autor:
B M, Boman, M M, Gagen, E, Bonnem, J A, Ajani, S, Schmidt, I W, Dimery, J, Golando, J, Neidhart
Publikováno v:
Journal of biological response modifiers. 7(5)
A Phase I study of recombinant gamma-interferon was conducted in 35 patients with advanced malignancy. The schedule was twice weekly administered intravenously. Patients were assigned to six dose levels. The major toxicities were flu-like symptoms an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ed8a7b66c8986f33a14996525dda2106
https://pubmed.ncbi.nlm.nih.gov/3141591
https://pubmed.ncbi.nlm.nih.gov/3141591
Autor:
K, Foon, J, Doroshow, E, Bonnem, A, Fefer, S, Graham, B, Grosh, P, Narayan, L, Elias, H, Harvey, R, Schulof
Publikováno v:
Journal of biological response modifiers. 7(6)
Eighty-nine patients with advanced measurable metastatic renal cell carcinoma were entered into a prospective randomized trial comparing alpha-interferon to gamma-interferon and to the combination. The trial was performed in order to confirm the acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e0d8d15ace88a3142c1ff80156d7ae79
https://pubmed.ncbi.nlm.nih.gov/3145964
https://pubmed.ncbi.nlm.nih.gov/3145964
Autor:
D C, Case, H L, Sonneborn, S D, Paul, J, Hiebel, M A, Boyd, M A, Shepp, B M, Dorsk, E, Bonnem
Publikováno v:
Cancer treatment reports. 70(11)
Twenty previously treated patients with multiple myeloma were treated with rDNA human alpha-2 interferon (INTRON A) in a phase II trial. Patients received an induction phase of therapy consisting of 3-100 X 10(6) IU/m2 iv given every other day pendin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c183ffb16a70392ec151f3461799b70d
https://pubmed.ncbi.nlm.nih.gov/3768870
https://pubmed.ncbi.nlm.nih.gov/3768870
Publikováno v:
Seminars in oncology. 13(3 Suppl 2)
Preclinical studies have suggested combination therapy with interferon and radiation results in an enhanced cytotoxic effect. Both additive and synergistic effects have been reported in mammalian cells in tissue culture. A phase I trial was designed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b3ff66be877921f491a1d13a0a830fd2
https://pubmed.ncbi.nlm.nih.gov/3764443
https://pubmed.ncbi.nlm.nih.gov/3764443